{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-026468","form_type":"8-K","ticker":"OZ","cik":"0001807046","company_name":"Belpointe PREP, LLC","filed_at":"2026-05-29T22:54:50+00:00","discovered_at":"2026-06-01T10:05:00.257717+00:00","generated_at":"2026-06-01T10:05:14.339981+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Belpointe PREP reports Q1 2026 NAV of $453.2M, or $116.25 per Class A unit","bullets":["NAV per Class A unit as of March 31, 2026 stood at $116.25, based on total NAV of $453.2M.","Total assets of $755.6M, including $724.8M in real property investments and $19.6M cash.","Total liabilities of $302.5M, comprising debt of $279.4M and other liabilities of $23.0M.","Number of Class A units outstanding was 3,898,104."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026468","json":"https://secwatch.observer/filing/0001493152-26-026468.json","markdown":"https://secwatch.observer/filing/0001493152-26-026468.md","text":"https://secwatch.observer/filing/0001493152-26-026468.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807046/000149315226026468/0001493152-26-026468-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807046/000149315226026468/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T10:05:14.339981+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001636282-26-000075","ticker":"SYRE","company_name":"Spyre Therapeutics, Inc.","filed_at":"2026-06-01T20:01:39+00:00","headline":"Spyre Therapeutics expands SPY003 license field beyond IBD with dosing restrictions until 2028-2030","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001636282-26-000075","json":"https://secwatch.observer/filing/0001636282-26-000075.json","markdown":"https://secwatch.observer/filing/0001636282-26-000075.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000075/0001636282-26-000075-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000075/syre-20260529.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-063481","ticker":"ORKA","company_name":"Oruka Therapeutics, Inc.","filed_at":"2026-06-01T20:01:27+00:00","headline":"Oruka Therapeutics expands ORKA-001 license to include IBD; clinical dosing restrictions until 2028-2030","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063481","json":"https://secwatch.observer/filing/0001213900-26-063481.json","markdown":"https://secwatch.observer/filing/0001213900-26-063481.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/907654/000121390026063481/0001213900-26-063481-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/907654/000121390026063481/ea0292876-8k_oruka.htm"},"side_by_side_evidence":null},{"accession":"0001606268-26-000032","ticker":"VIASP","company_name":"Via Renewables, Inc.","filed_at":"2026-06-01T19:06:57+00:00","headline":"Via Renewables to redeem all 1,884,935 shares of its 8.75% Series A Preferred at $25.00 per share plus dividends","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001606268-26-000032","json":"https://secwatch.observer/filing/0001606268-26-000032.json","markdown":"https://secwatch.observer/filing/0001606268-26-000032.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1606268/000160626826000032/0001606268-26-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1606268/000160626826000032/spke-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001437749-26-018969","ticker":"TRLC","company_name":"TriLinc Global Impact Fund LLC","filed_at":"2026-06-01T16:43:41+00:00","headline":"TriLinc Global Impact Fund portfolio assets ~$283M as of April 30, 2026","event_type":"other_material","sec_items":["8.01"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-018969","json":"https://secwatch.observer/filing/0001437749-26-018969.json","markdown":"https://secwatch.observer/filing/0001437749-26-018969.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1550453/000143774926018969/0001437749-26-018969-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1550453/000143774926018969/trlc20260513_8k.htm"},"side_by_side_evidence":null},{"accession":"0000015847-26-000009","ticker":"BUKS","company_name":"BUTLER NATIONAL CORP","filed_at":"2026-06-01T16:41:32+00:00","headline":"CEO Christopher Reedy discloses ongoing cancer treatment; remains in role","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000015847-26-000009","json":"https://secwatch.observer/filing/0000015847-26-000009.json","markdown":"https://secwatch.observer/filing/0000015847-26-000009.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/15847/000001584726000009/0000015847-26-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/15847/000001584726000009/buks-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001437749-26-018930","ticker":"CPSH","company_name":"CPS TECHNOLOGIES CORP/DE/","filed_at":"2026-06-01T13:35:50+00:00","headline":"CPS Technologies closes $9.6M registered direct offering of 1.2M shares at $8.00/share","event_type":"other_material","sec_items":["1.01","5.03","8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-018930","json":"https://secwatch.observer/filing/0001437749-26-018930.json","markdown":"https://secwatch.observer/filing/0001437749-26-018930.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/814676/000143774926018930/0001437749-26-018930-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/814676/000143774926018930/cpsh20260528_8k.htm"},"side_by_side_evidence":null},{"accession":"0001129928-26-000037","ticker":"ONCY","company_name":"ONCOLYTICS BIOTECH INC","filed_at":"2026-06-01T13:06:14+00:00","headline":"Oncolytics reports positive initial preclinical data for pelareorep + RAS inhibitors; further studies planned","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.45,"calibrated_materiality_score":0.45,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001129928-26-000037","json":"https://secwatch.observer/filing/0001129928-26-000037.json","markdown":"https://secwatch.observer/filing/0001129928-26-000037.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000037/0001129928-26-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000037/oncy-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-063185","ticker":"SILO","company_name":"Silo Pharma, Inc.","filed_at":"2026-06-01T13:02:13+00:00","headline":"Silo Pharma announces 1-for-15 reverse stock split effective June 2, 2026","event_type":"other_material","sec_items":["8.01"],"materiality_score":0.45,"calibrated_materiality_score":0.45,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063185","json":"https://secwatch.observer/filing/0001213900-26-063185.json","markdown":"https://secwatch.observer/filing/0001213900-26-063185.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1514183/000121390026063185/0001213900-26-063185-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1514183/000121390026063185/ea0292702-8k_silo.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}